aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) – Stock analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of aTyr Pharma in a report issued on Friday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($23.57) per share for the year, down from their previous forecast of ($15.60). The consensus estimate for aTyr Pharma’s current full-year earnings is ($17.80) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q4 2026 earnings at ($7.51) EPS, FY2027 earnings at ($10.65) EPS and FY2028 earnings at ($10.00) EPS.
Several other brokerages have also weighed in on ATYR. Wall Street Zen upgraded shares of aTyr Pharma to a “hold” rating in a report on Saturday, October 31st. Wells Fargo & Company raised their target price on aTyr Pharma from $1.00 to $4.00 and gave the company an “equal weight” rating in a research note on Friday. Royal Bank Of Canada decreased their target price on aTyr Pharma to $6.00 and set a “sector perform” rating for the company in a research report on Friday. Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. Finally, Freedom Broker lowered aTyr Pharma from a “strong-buy” rating to a “hold” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $5.00.
Get Our Latest Analysis on ATYR
aTyr Pharma Stock Performance
NASDAQ:ATYR opened at $7.58 on Tuesday. aTyr Pharma has a 12 month low of $4.07 and a 12 month high of $44.40. The firm has a fifty day simple moving average of $11.40 and a two-hundred day simple moving average of $23.48.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($7.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). The company had revenue of $235.23 million for the quarter, compared to the consensus estimate of $2.50 million.
Institutional Investors Weigh In On aTyr Pharma
An institutional investor recently raised its stake in aTyr Pharma stock. Bank of America Corp DE increased its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR – Free Report) by 139.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 303,559 shares of the company’s stock after acquiring an additional 176,859 shares during the period. Bank of America Corp DE owned about 0.31% of aTyr Pharma worth $237,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.
About aTyr Pharma
aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.
aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.
Read More
- Five stocks we like better than aTyr Pharma
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
